Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20416908 | 0.99 | PLA2G2A (0.37) | PLA2G2APLA2G4APLA2G10PRKDCPTPN1 | |
| SCHEMBL21127448 | 0.97 | PLA2G2A (0.37) | PLA2G2APLA2G4APLA2G10PRKDCPTPN1 | |
| SCHEMBL23849346 | 0.97 | PLA2G2A (0.37) | PLA2G2APLA2G4APLA2G10PRKDCPTPN1 | |
| SCHEMBL23060310 | 0.97 | PLA2G2A (0.37) | PLA2G2APLA2G4APLA2G10PRKDCPTPN1 | |
| SCHEMBL23109594 | 0.96 | PLA2G2A (0.35) | PLA2G2APLA2G4APLA2G10PTPN1PTPN2 | |
| SCHEMBL23919645 | 0.95 | PLA2G2A (0.33) | PLA2G2APLA2G4APLA2G10KDM4EMEN1 | |
| SCHEMBL21923886 | 0.95 | PLA2G2A (0.33) | PLA2G2APLA2G4APLA2G10KDM4EMEN1 | |
| SCHEMBL21150166 | 0.94 | PLA2G2A (0.33) | PLA2G2APLA2G4APLA2G10PTPN1PTPN2 | |
| SCHEMBL24208533 | 0.93 | MMP12 (0.35) | PLA2G2APLA2G4APLA2G10MMP12MMP13 | |
| SCHEMBL20374888 | 0.93 | ANO1 (0.32) | PLA2G2APLA2G4APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11569449-B2 | Organic electroluminescence device and novel compound | IDEMITSU KOSAN CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20190221747-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND NOVEL COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190221747-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND NOVEL COMPOUND | KCNN4, OR10J3, KCNN2 | PLA2G2A 3535/4885PLA2G4A 3868/4885PLA2G10 2229/4885 |
| US-11569449-B2 | Organic electroluminescence device and novel compound | PIEZO1, TMEM109, OXA1L | PLA2G2A 4620/4885PLA2G4A 4816/4885PLA2G10 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.